What is Lifesci Capital’s Estimate for Savara Q3 Earnings?

Savara Inc. (NASDAQ:SVRA) – Investment analysts at Lifesci Capital issued their Q3 2025 earnings estimates for Savara in a report issued on Tuesday, October 14th. Lifesci Capital analyst F. Brisebois expects that the company will post earnings of ($0.14) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. Lifesci Capital also issued estimates for Savara’s Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.55) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.51) EPS.

SVRA has been the topic of a number of other research reports. Guggenheim upped their price target on shares of Savara from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Oppenheimer upped their price target on shares of Savara from $6.00 to $8.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Wednesday, October 8th. Finally, HC Wainwright upped their price target on shares of Savara from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Savara Stock Performance

Shares of SVRA opened at $3.60 on Thursday. The company has a current ratio of 11.08, a quick ratio of 11.08 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $622.22 million, a P/E ratio of -7.20 and a beta of 0.46. The firm’s fifty day simple moving average is $3.35 and its two-hundred day simple moving average is $2.88. Savara has a 12 month low of $1.89 and a 12 month high of $4.30.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02).

Institutional Investors Weigh In On Savara

A number of institutional investors and hedge funds have recently made changes to their positions in SVRA. Rhumbline Advisers raised its holdings in shares of Savara by 8.6% in the 1st quarter. Rhumbline Advisers now owns 153,542 shares of the company’s stock worth $425,000 after acquiring an additional 12,117 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Savara by 25.3% in the 1st quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company’s stock worth $92,000 after acquiring an additional 6,532 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Savara by 3.7% in the 1st quarter. Bank of New York Mellon Corp now owns 262,935 shares of the company’s stock worth $728,000 after acquiring an additional 9,305 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its holdings in shares of Savara by 46.4% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 2,014,456 shares of the company’s stock worth $5,580,000 after acquiring an additional 638,568 shares during the last quarter. Finally, Emerald Advisers LLC raised its holdings in shares of Savara by 32.5% in the 1st quarter. Emerald Advisers LLC now owns 3,090,213 shares of the company’s stock worth $8,560,000 after acquiring an additional 757,533 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.